Insperity (NSP) Q1 2026 earnings review
Margin Recovery Takes Priority Over Growth
Insperity delivered exactly what it promised late last year: sacrificing worksite employee (WSEE) growth to repair heavily damaged margins. After a disastrous 2025 where healthcare claims crushed profitability, Q1 2026 results show the turnaround plan is taking hold. Aggressive repricing and new UnitedHealthcare contract terms sharply narrowed the Gross Profit contraction to -3% YoY (a massive improvement from Q4's -21% drop). Adjusted EBITDA returned to positive growth (+1%). However, this margin triage has a clear cost: WSEE volume fell 1% as price hikes drove planned attrition, and Q2 guidance points to further volume deceleration. Investors must now wait to see if the highly anticipated Workday HRScale launch can restart the top line in a sluggish SMB environment.
🐂 Bull Case
Gross Profit YoY decline narrowed from 21% in 25Q4 to just 3% in 26Q1. This validates that management's aggressive repricing and the new UHC contract are successfully offsetting the elevated healthcare claims that derailed 2025.
Operating expenses decreased 5% YoY (excluding a one-time restructuring charge), proving management is successfully aligning the cost structure with the currently lower unit volumes.
🐻 Bear Case
Average paid WSEEs shrank 1% YoY in Q1, and Q2 guidance projects an even steeper 1.5% to 2.1% decline. The company is actively shedding less profitable clients, putting intense pressure on the top line.
Core SMB hiring remains weak. Without organic net hiring from existing clients, any acceleration relies entirely on new sales and the upcoming HRScale launch.
⚖️ Verdict: ⚪
Neutral. The margin recovery is tracking well ahead of expectations and the worst of the healthcare cost shocks appear to be managed. However, with unit volumes actively shrinking and HRScale revenue still on the horizon, it is too early to declare an all-clear.
Key Themes
Aggressive Repricing Restores Profitability
The defining operational theme is the successful execution of Insperity's margin recovery plan. After benefits costs spiked dramatically in 2025, the company promised 'teens' percentage price hikes for 60% of the renewing client base. Q1 numbers show this is working: Gross Profit was down only 3% YoY to $302M, a stark reversal from the 21% YoY collapse in 25Q4. Benefits costs per covered employee rose 5%—still elevated, but manageable against higher pricing and the lowered risk pooling in the new UHC contract.
WSEE Volume Bleed
The direct consequence of the margin recovery is client attrition. Average paid WSEEs fell 1% to 303,049 in Q1. Management clearly telegraphed this trade-off, citing the non-renewal of unprofitable accounts. However, Q2 guidance implies a further deceleration to a 1.8% midpoint decline. The key monitoring point will be how quickly the sales engine can replace this 'bad' volume with 'good' volume later in the year.
Restructuring and OpEx Control
Management took a $9 million restructuring charge in Q1, primarily for severance related to workforce realignment. This aligns with the 4% non-sales headcount reduction planned at the end of 2025. Excluding this charge, operating expenses decreased 5% YoY to $231M. This tight cost control is vital to generating the operating leverage required for the FY26 EBITDA guidance.
Workday Partnership Progress (HRScale)
Operating expenses included $8M related to the Workday strategic partnership in Q1 (down from $13M a year ago). As the HRScale platform approaches its rollout to mid-market clients (150-5,000 employees), this remains the company's primary catalyst for returning to unit growth in 2027. However, with limited financial contribution expected in 2026, it requires patience.
Other KPIs
Accelerating. Increased 3% YoY, up from $2,029 in Q1 2025. This metric explicitly proves the pricing increases are sticking across the client base, successfully offsetting the 1% decline in overall volume to generate 2% total revenue growth.
Down from $57 million at the end of 2025. During the quarter, the company spent $4 million repurchasing 171,000 shares, paid $23 million in dividends, and executed $6 million in CapEx. The company retains $370 million in outstanding borrowings on its credit facility.
Guidance
Decelerating. This range implies a YoY decrease of 1.5% to 2.1%. With Q1 shrinking 1.0%, this indicates the volume bleed from repricing and sluggish SMB hiring will deepen into the summer before any stabilization occurs.
Stable. The midpoint ($32 million) is perfectly flat compared to the $32 million generated in Q2 2025. This is a reasonable expectation given that volume is shrinking, but gross margins per employee are recovering.
The full-year range implies a contraction of 1.0% to 2.3% YoY. Given the Q1 exit rate, achieving the top end of this range will require a noticeable uptick in net client hiring or new sales in H2 2026.
Accelerating significantly versus 2025's battered baseline of $131 million. Management is holding firm to the guidance initiated at the end of 2025, implying a 30% to 76% YoY growth rate. The Q1 beat provides a strong foundation to achieve this.
Key Questions
Separating Attrition vs. Macro Softness
Of the 1% decline in WSEEs, how much was directly attributable to planned non-renewals and pricing-driven churn, versus a lack of net hiring among the remaining healthy client base?
HRScale Visibility
With the beta clients going live this quarter, what is the hard backlog of committed worksite employees transitioning onto the HRScale platform for the second half of 2026?
Healthcare Claim Tail Risk
Benefits costs increased 5% YoY. Have the new UHC contract provisions fully insulated the company from the sudden mid-quarter claim spikes and prior-period runoff that caused the 2025 guidance cuts?